Cardiology & Clinical Observations for Acquired Brain Injury
Systematic cardiovascular monitoring — identifying autonomic dysfunction, medication cardiac risk, and ensuring physical stability underpins neurological recovery.
Cardiovascular health is a critical and frequently overlooked dimension of Acquired Brain Injury recovery. Autonomic nervous system dysfunction — a common and underappreciated sequela of both traumatic and hypoxic brain injury — can produce dysautonomia, orthostatic hypotension, postural tachycardia syndrome (PoTS), cardiac arrhythmias, labile blood pressure and abnormal heart rate variability. These presentations are frequently misidentified as anxiety, behavioural disturbance or medication side effects in ABI patients — leading to inappropriate treatment and delayed diagnosis.
Additionally, many of the medications routinely prescribed post-ABI carry clinically significant cardiac side effect profiles that mandate structured monitoring. Failure to monitor appropriately in this group exposes patients to preventable cardiac events and exposes clinical teams and deputies to governance risk.
Our medically supervised weight management programme addresses these root causes with a bespoke, clinically structured plan that integrates dietary guidance, physical activity support, pharmacological intervention where appropriate and clinically indicated, and ongoing monitoring and reporting to the care team.
Routine clinical observations
- Blood pressure — manual auscultatory method and validated automated device
- Orthostatic blood pressure protocol: lying (5 min), standing at 1 min, 3 min and 5 min — standard for dysautonomia detection
- Heart rate and rhythm — radial pulse assessment and rhythm documentation
- Respiratory rate — counted at rest for 60 seconds
- Peripheral oxygen saturation (SpO2) and waveform quality
- Temperature — tympanic or axillary
- Peripheral oedema assessment — bilateral lower limb grading
- Capillary refill time and peripheral circulation assessment
ECG and cardiac monitoring
- 12-lead resting ECG using portable medical-grade equipment — conducted in-home
- Automated and manual interpretation — abnormal traces reviewed by clinician with cardiology training
- QTc interval measurement and documentation — critical for patients on QT-prolonging medications
- PR interval and QRS duration assessment
- Arrhythmia identification: atrial fibrillation, atrial flutter, heart block, ectopic activity
- Onward referral to NHS cardiology via GP or direct pathway where significant abnormalities identified
- ECG trace retained in clinical records and available to case managers and deputies on request
Autonomic function assessment
- Full orthostatic hypotension assessment per 2018 ESC guidelines (lying-to-standing BP and HR protocol)
- Heart rate variability assessment
- Identification and clinical management of neurogenic orthostatic hypotension
- Screening for postural tachycardia syndrome (PoTS) — increasingly recognised post-COVID and post-TBI
- Syncope and pre-syncope assessment in the context of ABI and falls risk
- Medication review for agents contributing to autonomic instability
- Dysautonomia documented and reported to MDT with recommendations for management
Medication-specific cardiac monitoring programmes
The following medication classes commonly prescribed post-ABI require structured cardiac surveillance — Nexus ABI coordinates and documents this monitoring as part of the patient's clinical record:
Antipsychotics (first and second generation)
- QTc prolongation risk — significant and class-wide
- Baseline ECG mandatory before initiation of any antipsychotic
- Repeat ECG at 1 month and 3 months post-initiation, then 6-monthly
- Clozapine-specific: mandatory CPMS registration, weekly FBC for 18 weeks, fortnightly for 52 weeks, then 4-weekly — cardiac and metabolic monitoring programme managed in full by Nexus ABI
- Metabolic monitoring programme: weight, BP, fasting glucose, HbA1c, lipids at baseline, 3 months, 6 months, annually
Other ABI medications requiring cardiac monitoring
- Methylphenidate and other stimulants for ABI-related attention deficit — BP and HR monitoring required at each titration step and quarterly on stable dose
- Lithium — ECG at baseline and if bradycardia, arrhythmia or T-wave abnormalities develop
- Anticonvulsants — sodium channel blockers (carbamazepine, phenytoin, lacosamide) — PR interval prolongation risk
- Tricyclic antidepressants — QTc monitoring
- Methadone — significant QTc risk; ECG at baseline, dose increases and if clinically indicated
- Domperidone — QTc prolongation at higher doses — monitoring if co-prescribed with other QTc-prolonging agents
Frequently Asked Questions
Our FAQ section is here to answer the most common questions about this service and help you feel fully informed before getting started. If you don’t see the answer you’re looking for, please don’t hesitate to get in touch—our team is always happy to help and provide clarity where needed.
Why do patients with Acquired Brain Injury need specialist cardiovascular monitoring?
Acquired Brain Injury — particularly traumatic brain injury, hypoxic injury and stroke — frequently disrupts the autonomic nervous system, which regulates heart rate, blood pressure, vascular tone and cardiac rhythm. The resulting autonomic dysfunction can produce orthostatic hypotension, postural tachycardia syndrome (PoTS), cardiac arrhythmias, labile blood pressure and impaired heart rate variability. These presentations are often misidentified as anxiety or behavioural disturbance in ABI patients. Additionally, many post-ABI medications carry clinically significant cardiac side effects — including QTc interval prolongation — that mandate structured monitoring to prevent potentially fatal arrhythmias.
What is a 12-lead ECG and why is it important for ABI patients?
A 12-lead ECG is a non-invasive recording of the electrical activity of the heart from 12 different angles, providing a comprehensive picture of cardiac rhythm, conduction and structural changes. For ABI patients it is particularly important because: (1) many commonly prescribed medications — antipsychotics, antidepressants, anticonvulsants, methadone — prolong the QTc interval (the heart’s electrical recovery time), increasing the risk of a potentially fatal arrhythmia called Torsades de Pointes; and (2) autonomic dysfunction can produce rhythm changes that are directly attributable to neurological injury. Baseline and periodic ECGs are therefore a clinical governance requirement for patients on QT-prolonging medications.
What is QTc interval monitoring and which medications require it?
The QTc interval is a measurement on the ECG that reflects the heart’s electrical recovery time, corrected for heart rate. Prolongation of this interval — particularly above 500ms — significantly increases the risk of serious ventricular arrhythmia. Many medications prescribed post-ABI prolong the QTc, including all antipsychotics (particularly haloperidol, quetiapine and clozapine), tricyclic antidepressants, methadone, some anticonvulsants (carbamazepine, lacosamide), and some antiemetics and antibiotics when co-prescribed. NICE and Maudsley prescribing guidelines specify baseline and follow-up ECG requirements for each of these — Nexus ABI coordinates and documents this monitoring as part of our cardiology service.
What is autonomic dysfunction and how does it present after brain injury?
Autonomic dysfunction — also called dysautonomia — occurs when brain injury disrupts the neural pathways that control involuntary bodily functions. After ABI, this commonly presents as orthostatic hypotension (a significant blood pressure drop on standing, causing dizziness, falls and loss of consciousness), postural tachycardia syndrome (PoTS — an excessive heart rate rise on standing), paroxysmal autonomic instability (episodes of hypertension, tachycardia, hyperthermia and sweating), and impaired heart rate variability. These presentations are frequently attributed to medications or anxiety rather than diagnosed as autonomic sequelae of the brain injury, leading to inappropriate management.
What is orthostatic hypotension and how is it tested?
Orthostatic hypotension is defined as a drop in systolic blood pressure of 20mmHg or more, or diastolic blood pressure of 10mmHg or more, within 3 minutes of standing. It is a common and clinically important finding in ABI patients — causing falls, syncope, fatigue and reduced rehabilitation capacity. Our clinical team performs a standardised orthostatic protocol: blood pressure and heart rate are recorded after 5 minutes lying, then at 1, 3 and 5 minutes standing, in line with 2018 ESC consensus guidelines. Concurrent heart rate assessment allows differentiation between neurogenic orthostatic hypotension and PoTS.
Can Nexus ABI manage clozapine monitoring?
Yes. Clozapine is subject to mandatory monitoring requirements under the UK Clozapine Patient Monitoring Service (CPMS) — including mandatory haematology monitoring (white cell count and neutrophil count weekly for 18 weeks, fortnightly for 52 weeks, then 4-weekly on an ongoing basis) and metabolic monitoring (weight, blood glucose, lipids and blood pressure at defined intervals). Cardiac monitoring — baseline ECG and monitoring for QTc prolongation, myocarditis symptoms and metabolic cardiomyopathy risk — is also required. Nexus ABI can manage the complete clozapine monitoring programme, coordinating bloods via our phlebotomy service, ECGs via our cardiology service, and clinical review via our Remote GP service.
How often should cardiovascular observations be carried out for ABI patients?
Frequency depends on the patient’s clinical profile and medications. Patients on QT-prolonging medications should have a baseline ECG before initiation, a repeat at 1 month and 3 months, then 6-monthly on a stable dose — or more frequently if the dose changes or clinical concerns arise. Routine clinical observations (BP, HR, SpO2) should be carried out at each clinical visit. Patients with known autonomic dysfunction, a history of syncope or falls, or labile blood pressure should have more structured monitoring with documented orthostatic assessments at regular intervals.
What happens if an abnormal ECG or blood pressure reading is found?
Abnormal findings are reviewed by the attending clinician at the time of the visit and reported to our supervising clinician the same day. The clinical response depends on the severity and nature of the finding: a mildly prolonged QTc in the context of a new medication may prompt a medication review; a new arrhythmia may require urgent NHS cardiology referral; a haemodynamically significant blood pressure finding may require immediate management and escalation. All abnormal findings are documented, the case manager is informed, and a clinical recommendation is produced within 24 hours.
Are the ECG results interpreted by a cardiologist?
ECG traces are interpreted by a Nexus ABI clinician with training in clinical ECG interpretation. Where a trace shows significant abnormality — new arrhythmia, significant QTc prolongation, conduction block or ST segment changes — we arrange for review by an NHS cardiologist via GP referral or, where urgency dictates, direct emergency pathway. ECG traces are retained in the patient’s clinical record and are available to the case manager and deputy for their records.
How is cardiovascular monitoring funded?
Cardiology observations and ECGs are funded through personal injury settlement budgets, Court of Protection deputyship funds, and NHS Continuing Healthcare where appropriate. Standalone ECG pricing and clinical observation visit pricing are available on our Fees & Funding page. When cardiac monitoring is delivered as part of a combined in-home visit alongside phlebotomy or diagnostic monitoring, bundled visit pricing applies.